This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lung cancer	VEGF receptor 1 (FLT1)	<p>Mouse studies suggest inhibiting FLT1 could help prevent chemotherapy-induced lung metastases. In mice, cisplatin followed by injection of mouse colon cancer or melanoma cell lines resulted in a greater number of lung metastases than injection of vehicle and cancer cell lines. However, pretreatment with cisplatin plus an anti-Flt1 antibody resulted in fewer lung metastases than pretreatment with cisplatin or antibody alone. Future studies could include testing cisplatin and the anti-Flt1 antibody in additional mouse models of metastatic cancer.</p> <p>Votrient pazopanib, a broad-spectrum inhibitor of FLT1 and other tyrosine kinases from GlaxoSmithKline plc, is approved to treat renal cancer and is in Phase III testing to treat ovarian and breast cancers and sarcoma.</p> <p>Pfizer Inc.'s axitinib (AG-013736), an inhibitor of FLT1, VEGF receptor 2 (KDR/Flk-1; VEGFR-2) and VEGF receptor 3 (FLT4), is under review to treat renal cancer and is in Phase II testing to treat breast, gastrointestinal, lung and thyroid cancers.</p> <p>Recentin cediranib, an inhibitor of FLT1, VEGFR-2 and FLT4 from AstraZeneca plc, is in Phase II testing to treat non-small cell lung cancer (NSCLC), and renal and prostate cancers.</p> <p>SciBX 4(42); doi:10.1038/scibx.2011.1176 Published online Oct. 27, 2011</p>	Unpatented; licensing status undisclosed	<p>Daenen, L.G.M. <i>et al. Cancer Res.</i>; published online Oct. 5, 2011; doi:10.1158/0008-5472.CAN-11-0627</p> <p>Contact: Emile E. Voest, University Medical Center Utrecht, Utrecht, the Netherlands e-mail: e.e.voest@umcutrecht.nl</p>